Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey

M. Terrin, S. Z. Goldhaber, B. Thompson, R. C. Bone, S. R. Braun, W. Bria, S. E. Buchalter, R. J. Castriotta, M. Chatham, A. Cosentino, G. Elliott, P. Fahey, W. Friedenberg, J. Gadek, I. Goldenberg, J. E. Grossman, W. Haire, D. Heiselman, J. Heit

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

During a recent one-year period, 44 clinical centers in the United States saw 2,539 patients with diagnoses of pulmonary embolism as supported by high probability lung scans and/or positive pulmonary angiograms. In developing proposals for a clinical trial of Thrombolysis in Pulmonary Embolism (TIPE), investigators in the 44 clinical centers reviewed the 2,539 patients' medical charts for contraindications to thrombolytic therapy. Overall, 1,345 (53.5%) patients surveyed in the TIPE clinical centers would have been acceptable for treatment with thrombolytic therapy, a proportion higher than generally anticipated. Risks of major blood loss were the most frequent contraindications to thrombolytic therapy and were found in 838 (33.3%) patients. Risks to the CNS were found to contraindicate thrombolytic therapy in 453 (17.9%) patients. Risks of bleeding into special compartments were found to contraindicate thrombolytic therapy in 76 (3.0%) patients. Pulmonary embolism is underdiagnosed in most clinical settings, and even more patients than found in the TIPE survey could benefit from appropriate diagnosis and treatment. The question remains as to whether pulmonary embolism patients will benefit from thrombolytic therapy. Only a randomized clinical trial will provide a satisfactory answer.

Original languageEnglish (US)
JournalChest
Volume95
Issue number5 SUPPL.
StatePublished - 1989
Externally publishedYes

Fingerprint

Thrombolytic Therapy
Pulmonary Embolism
Patient Selection
Lung
Surveys and Questionnaires
Angiography
Randomized Controlled Trials
Research Personnel
Clinical Trials
Hemorrhage
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Terrin, M., Goldhaber, S. Z., Thompson, B., Bone, R. C., Braun, S. R., Bria, W., ... Heit, J. (1989). Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey. Chest, 95(5 SUPPL.).

Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey. / Terrin, M.; Goldhaber, S. Z.; Thompson, B.; Bone, R. C.; Braun, S. R.; Bria, W.; Buchalter, S. E.; Castriotta, R. J.; Chatham, M.; Cosentino, A.; Elliott, G.; Fahey, P.; Friedenberg, W.; Gadek, J.; Goldenberg, I.; Grossman, J. E.; Haire, W.; Heiselman, D.; Heit, J.

In: Chest, Vol. 95, No. 5 SUPPL., 1989.

Research output: Contribution to journalArticle

Terrin, M, Goldhaber, SZ, Thompson, B, Bone, RC, Braun, SR, Bria, W, Buchalter, SE, Castriotta, RJ, Chatham, M, Cosentino, A, Elliott, G, Fahey, P, Friedenberg, W, Gadek, J, Goldenberg, I, Grossman, JE, Haire, W, Heiselman, D & Heit, J 1989, 'Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey', Chest, vol. 95, no. 5 SUPPL..
Terrin, M. ; Goldhaber, S. Z. ; Thompson, B. ; Bone, R. C. ; Braun, S. R. ; Bria, W. ; Buchalter, S. E. ; Castriotta, R. J. ; Chatham, M. ; Cosentino, A. ; Elliott, G. ; Fahey, P. ; Friedenberg, W. ; Gadek, J. ; Goldenberg, I. ; Grossman, J. E. ; Haire, W. ; Heiselman, D. ; Heit, J. / Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey. In: Chest. 1989 ; Vol. 95, No. 5 SUPPL.
@article{5b3f5d1bf03b4eeb9bd4740d22368eed,
title = "Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey",
abstract = "During a recent one-year period, 44 clinical centers in the United States saw 2,539 patients with diagnoses of pulmonary embolism as supported by high probability lung scans and/or positive pulmonary angiograms. In developing proposals for a clinical trial of Thrombolysis in Pulmonary Embolism (TIPE), investigators in the 44 clinical centers reviewed the 2,539 patients' medical charts for contraindications to thrombolytic therapy. Overall, 1,345 (53.5{\%}) patients surveyed in the TIPE clinical centers would have been acceptable for treatment with thrombolytic therapy, a proportion higher than generally anticipated. Risks of major blood loss were the most frequent contraindications to thrombolytic therapy and were found in 838 (33.3{\%}) patients. Risks to the CNS were found to contraindicate thrombolytic therapy in 453 (17.9{\%}) patients. Risks of bleeding into special compartments were found to contraindicate thrombolytic therapy in 76 (3.0{\%}) patients. Pulmonary embolism is underdiagnosed in most clinical settings, and even more patients than found in the TIPE survey could benefit from appropriate diagnosis and treatment. The question remains as to whether pulmonary embolism patients will benefit from thrombolytic therapy. Only a randomized clinical trial will provide a satisfactory answer.",
author = "M. Terrin and Goldhaber, {S. Z.} and B. Thompson and Bone, {R. C.} and Braun, {S. R.} and W. Bria and Buchalter, {S. E.} and Castriotta, {R. J.} and M. Chatham and A. Cosentino and G. Elliott and P. Fahey and W. Friedenberg and J. Gadek and I. Goldenberg and Grossman, {J. E.} and W. Haire and D. Heiselman and J. Heit",
year = "1989",
language = "English (US)",
volume = "95",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey

AU - Terrin, M.

AU - Goldhaber, S. Z.

AU - Thompson, B.

AU - Bone, R. C.

AU - Braun, S. R.

AU - Bria, W.

AU - Buchalter, S. E.

AU - Castriotta, R. J.

AU - Chatham, M.

AU - Cosentino, A.

AU - Elliott, G.

AU - Fahey, P.

AU - Friedenberg, W.

AU - Gadek, J.

AU - Goldenberg, I.

AU - Grossman, J. E.

AU - Haire, W.

AU - Heiselman, D.

AU - Heit, J.

PY - 1989

Y1 - 1989

N2 - During a recent one-year period, 44 clinical centers in the United States saw 2,539 patients with diagnoses of pulmonary embolism as supported by high probability lung scans and/or positive pulmonary angiograms. In developing proposals for a clinical trial of Thrombolysis in Pulmonary Embolism (TIPE), investigators in the 44 clinical centers reviewed the 2,539 patients' medical charts for contraindications to thrombolytic therapy. Overall, 1,345 (53.5%) patients surveyed in the TIPE clinical centers would have been acceptable for treatment with thrombolytic therapy, a proportion higher than generally anticipated. Risks of major blood loss were the most frequent contraindications to thrombolytic therapy and were found in 838 (33.3%) patients. Risks to the CNS were found to contraindicate thrombolytic therapy in 453 (17.9%) patients. Risks of bleeding into special compartments were found to contraindicate thrombolytic therapy in 76 (3.0%) patients. Pulmonary embolism is underdiagnosed in most clinical settings, and even more patients than found in the TIPE survey could benefit from appropriate diagnosis and treatment. The question remains as to whether pulmonary embolism patients will benefit from thrombolytic therapy. Only a randomized clinical trial will provide a satisfactory answer.

AB - During a recent one-year period, 44 clinical centers in the United States saw 2,539 patients with diagnoses of pulmonary embolism as supported by high probability lung scans and/or positive pulmonary angiograms. In developing proposals for a clinical trial of Thrombolysis in Pulmonary Embolism (TIPE), investigators in the 44 clinical centers reviewed the 2,539 patients' medical charts for contraindications to thrombolytic therapy. Overall, 1,345 (53.5%) patients surveyed in the TIPE clinical centers would have been acceptable for treatment with thrombolytic therapy, a proportion higher than generally anticipated. Risks of major blood loss were the most frequent contraindications to thrombolytic therapy and were found in 838 (33.3%) patients. Risks to the CNS were found to contraindicate thrombolytic therapy in 453 (17.9%) patients. Risks of bleeding into special compartments were found to contraindicate thrombolytic therapy in 76 (3.0%) patients. Pulmonary embolism is underdiagnosed in most clinical settings, and even more patients than found in the TIPE survey could benefit from appropriate diagnosis and treatment. The question remains as to whether pulmonary embolism patients will benefit from thrombolytic therapy. Only a randomized clinical trial will provide a satisfactory answer.

UR - http://www.scopus.com/inward/record.url?scp=0024588660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024588660&partnerID=8YFLogxK

M3 - Article

VL - 95

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5 SUPPL.

ER -